Company news

Moleculin Biotech, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

October 13, 2022

Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral

September 26, 2022

Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme

September 5, 2022

Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

August 18, 2022

Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update

August 14, 2022

Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

July 27, 2022

Moleculin Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

July 7, 2022

Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

June 15, 2022

Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

May 25, 2022

Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update

May 11, 2022

Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

May 9, 2022

Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

May 4, 2022

Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

May 3, 2022

Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma

April 20, 2022

Moleculin Announces Corporate Rebranding and Launch of New Website

April 13, 2022

Moleculin Reports Full Year Financial Results and Provides Programs Update

March 24, 2022

Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors

February 28, 2022

Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development

February 13, 2022

Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma

January 17, 2022

Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

December 26, 2021

Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme

November 30, 2021

Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update

November 10, 2021

Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

October 18, 2021

Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

October 17, 2021

Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update

August 11, 2021

Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia

July 12, 2021

Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

June 20, 2021

Moleculin Announces Inclusion in the Russell 2000® Index

June 14, 2021

Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

May 24, 2021

Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update

May 11, 2021

Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma

April 13, 2021

Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial

April 5, 2021

Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases

March 29, 2021

Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020

March 23, 2021

Moleculin Announces Full Exercise of Over-Allotment Option

February 9, 2021

Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases

February 7, 2021

Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering

February 2, 2021

Moleculin Announces Proposed Underwritten Public Offering

February 1, 2021

Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial

January 31, 2021

Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

December 28, 2020

Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases

December 16, 2020

Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference

December 2, 2020

Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066

November 30, 2020

Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML

November 18, 2020

Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020

November 12, 2020

Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19

October 28, 2020

Moleculin Announces Independent Study Validates Annamycin's Ability to Target Lung Localized Tumors

October 20, 2020

Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial

October 12, 2020

Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV

October 5, 2020

Moleculin Appoints Elizabeth Cermak to Board of Directors

October 4, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 53 decks. Every deck is listed under its year.